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K. Chan
Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SAR, PR ChinaAbstract
A World Health Organisation survey indicated that about 70–80% of the world populations rely on non-conven-
tional medicine mainly of herbal sources in their primary healthcare. In recent years, we have witnessed the increasing
growth in popularity of over-the-counter (OTC) health foods, nutraceuticals, and medicinal products from plants or
other natural sources in developed countries. This indirectly indicates that the public is not satisﬁed with their orthodox
medical (OM) treatment. Such increase in popularity has also brought concerns and fears over the professionalism of
practitioners, and quality, eﬃcacy and safety of their treatment methods and products from herbal and natural sources
available in the market. Over the past decade several news-catching episodes in developed communities indicated
adverse eﬀects, sometimes life threatening, allegedly arisen consequential to taking of OTC herbal products or tradi-
tional medicines from various ethnic groups. These OTC products may be contaminated with excessive or banned
pesticides, microbial contaminants, heavy metals, chemical toxins, and for adulterated with orthodox drugs. Excessive
or banned pesticides, heavy metals and microbial contaminants may be related to the source of these herbal materials, if
they are grown under contaminated environment or during collection of these plant materials. Chemical toxins may
come from unfavourable or wrong storage conditions or chemical treatment due to storage. The presence of orthodox
drugs can be related to unprofessional practice of manufacturers. Some of these environment related factors can be
controlled by implementing standard operating procedures (SOP) leading to Good Agricultural Practice (GAP), Good
Laboratory Practice (GLP), Good Supply Practice (GSP) and Good Manufacturing Practice (GMP) for producing
these medicinal products from herbal or natural sources. The publics belief that herbal and natural products are safer
than synthetic medicines can only be ascertained by imposing regulatory standards on these products that should be
manufactured using these Good Practices.
Using Chinese medicines, as examples, this paper illustrate how advances in chemical and biomedical analysis would
help to detect intentional and unintentional toxic contaminants in herbal substances. The paper also summarises how
modernization and progress are being carried out to get the best out of Chinese medicines for public healthcare.
 2003 Elsevier Ltd. All rights reserved.
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About 70–80% of the world populations, particularly
in the developing countries, rely on non-conventional
medicine in their primary healthcare as reported by the
World Health Organisation (Akerele, 1993). The rest of
the populations, in the better-developed countries, have
been fortunate receivers of orthodox medicine (OM) or
conventional medicine since the early 19th century. Yet in
the present era of rapid advances in biomedical science
and technology it is astonishing that the public in rich
developed countries spends an signiﬁcant amount of their
earnings on over-the-counter (OTC) herbal products and
related non-conventional therapies. Over the past decade
we have witnessed two apparently unrelated trends in the
biomedical and biotechnological development of medic-
inal products. There is the rapid development of recom-
binant DNA technology and related procedures to
provide biomedical proteins and related biological
products for use as therapeutic drugs, prophylactic vac-
cines and diagnostic agents (Chan, 1996). The growth in
popularity of OTC health foods (nutraceuticals) and
medicinal products from plants or other natural sources
have taken a very large share of the healthcare market
(Johnson, 1997). These two unrelated trends indicate
changes in peoples perceptions of OM treatment using
synthetic drugs or conventional therapies.
1.1. Increasing use of complementary or alternative
medicines
In most developed countries where OM assumes full
responsibility in national healthcare, where as mostforms of traditionally practised medicine and therapies
are considered as complementary or alternative medi-
cine (CAM). Some experts consider that OM is allo-
pathic treatment while many of the CAM involve
holistic approach; the practitioners of OM attempt to
intervene in order to block certain body processes while
practitioners of the CAM focus on supporting and
working with the bodys innate powers of self-regener-
ation. The WHO has deﬁned CAM as all forms of
healthcare provision which usually lie outside the oﬃ-
cial health sector (Eisenberg et al., 1993). This deﬁnition
by WHO embraces formalised traditional systems of
medicine (Ayurvedic,Chinese,HindooandUnani systems
etc.), traditional healers and medicine men, feedback,
chiropractic, naturopathy, osteopathy, and homeopathy
etc. Very little is known concerning the reasons for the
increase in popularity of CAM in developed countries.
Untested assumptions include the side-eﬀects of syn-
thetic drugs, general dissatisfaction of orthodox treat-
ment, diseases that cannot be cured by OM, and patients
with chronic illnesses demanding more attention from
OM practitioners. Research is urgently needed in these
areas to improve healthcare planning (Chan, 1996). CAM
treatments are recommended for chronic pain aﬀecting
spine, joints or muscles, for the control of nausea, ec-
zema, and other skin complaints, asthma, cancer and
migraine etc. (Lewith et al., 1996). There are over 100
diﬀerent therapies available as CAM treatments, but the
ﬁve discrete clinical disciplines (acupuncture, chiro-
practic, herbal medicine, homeopathy and osteopathy)
are distinguished by having established foundations of
training and professional standards (British Medical
Association, 1993). However it has been pointed out that
Table 1
Suspected adverse eﬀects of complementary/alternative medicine (modiﬁed from Abbot et al. (1996) and Barnes (1997))
Users survey General practitioners survey
Therapy % Reporting AEs Most commonly
reported AEs
% Reporting
AEs
Most commonly
reported minor AEs
Most commonly
reported major AEs
Manipulation 15.8 (24) Pain (13) 15.4 (71) Aggravation (65) Fractures (3)
Fatigue (2) Nerve Damage (2)
Dizziness (3) Disk Protrusion (1)
Acupuncture 12.5 (23) Aggravation (6) <0.1 (4) Aggravation (2) Septic Arthritis (1)
Mental Eﬀects (3) Visual Disturbance (1)
Fatigue (3)
Pain (2)
Needle trauma (2)
Homeopathy 9.8 (28) Aggravation (6) <0.1 (9) Aggravation (5) Liver Failure (1)
Mental Eﬀects (3) Eye Infection (1) Anaphylaxis (1)
Digestive Eﬀects (2) Skin Rash (1)
Herbal
medicine
7.6 (10) Digestive Eﬀects (3) <0.1 (6) Aggravation (2) Liver Toxicity (1)
Rashes (2)
Nausea (1)
Where AE¼ adverse eﬀects; numbers in brackets ( ) refer to actual reported incidents.
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free from adverse eﬀects (Table 1) (Abbot et al., 1996;
Barnes, 1997).
1.2. The emerging market of herbal products
Herbal or medicinal plant products in various forms
have been available for many hundreds of years for
treatment of diseases in both Eastern and Western cul-
tures. About one-quarter of marketed orthodox phar-
maceutical medicines is either derived from plant
sources or from derivatives of secondary plant metabo-
lites. The success of obtaining new drugs from natural
sources is not very encouraging. Several factors are re-
sponsible for such observation (Chaudhury, 1992). At
present, of about 2000 varieties of minor illnesses and
serious diseases only 40% have cure using conventional
orthodox pharmaceuticals (Abbot et al., 1996). Vari-
ous chemicals and biotechnological products are being
screened by major multinational pharmaceutical indus-
tries in the hope of discovering new cures for diseases.
Table 2 shows the diﬀerent types of herbal medicines
being practised. It is interested to note that China has a
US$1.3 billion turnover of herbs used in Chinese medi-
cine. In Europe there is signiﬁcant amount, in the vi-
cinity of about £300 million, of herbal remedies that the
public consumes. In the 1997 meeting of Federation of
International Pharmcaceutique (FIP), an oﬃcer from
United State Pharmacopoeia (USP) indicated a steady
increase of 10% in public spending on remedies of bo-
tanical origins. In the same meeting another oﬃcial from
the Food and Drug Administration (FDA) indicated the
concern on adverse eﬀects induced by consumption ofremedies of natural sources including botanicals. The
emerging importance of herbal products cannot be ig-
nored. Aspects of the eﬃcacy, safety and quality of
herbal or natural products are the subjects of on-going
debates.
1.3. The growing popularity of Chinese medicinal herbs
and herbal products in the west
Chinese medicinal (CM) products have received most
attention and recently gained popularity and attention
in the West. Increasing information on CM has been
published in the English literature and the debate of
eﬃcacy of CM products has begun (Chan, 1995). Ze-
maphyte, consisting of 10 diﬀerent CM herbs in the form
of an aqueous decoction for the successful cure of atopic
eczema, that has been resistant to orthodox treatment,
has created greater interest and attention on the use of
CM herbs and proprietary products (Atherton et al.,
1992). Increasing concern and fear have also been ex-
pressed to their unsupervised use, eﬃcacy, toxicity and
quality of these natural products as well as the legal
responsibilities of practitioners. Inclusion of orthodox
medications such as antibiotics, non-steroidal drugs and
steroids in CM patent products was not considered as a
positive attribute of CM in the West (Karunanithy and
Sumita, 1991). The use of fake or wrong herbs has
contributed a negative opinion about the safety and ef-
ﬁcacy of CM products (Jin et al., 1995). Many popular
and expensive CM herbs are in short supply and inferior
substitutes or fake crude herbs have been found in the
UK market (Yu et al., 1995, 1997). Thus, the increasing
popularity of herbal products as medications and food
Table 3
A comparison between properties of Chinese medicinal mate-
rials and products and orthodox drugs (adopted from Chan
(1995))
Properties Remarks
Table 2
Medicinal products from natural sources in various ethnic cultures
Complementary medicine Natural sources Origins Recent turnover trade
Ayurvedic P, A, M India No ﬁgure
Chinese P, A, M China >1.3 billion US$
Indusyunic P, A, M Pakistan No ﬁgure
Islamic P, A, M Middle East No ﬁgure
Kampo P, A, M Japan Getting competitive
Korean P, A, M Korea No ﬁgure
Other oriental P, A, M Other Asian countries No ﬁgure
Aromatherapy P European £14 m in 1996 (UK ﬁgure)
Herbalism P European £38 m in 1996 (UK ﬁgure)
Homoeopathy P European £20 m in 1996 (UK ﬁgure)
Botanicals P American 10% annual increase
P: medicinal plants, A: animal sources, M: mineral sources.
1364 K. Chan / Chemosphere 52 (2003) 1361–1371supplements has also produced fear about their quality,
safety and eﬃcacy (QSE) with uncertainty about their
active compounds (Ernst and De Smet, 1996). This is
probably because of the increasing use is causing a short-
age of the raw materials and unprofessional trading.CMM products Orthodox
drugs
Physico-chemical properties
Active ingredients Often unknown Known
Availability of pure
compound
Rare Yes
Availability of raw
material
Limited Yes
Quality of raw mate-
rial
Variable Good
Stability of prepara-
tion
Uncertain Good
Biomedical properties
Mechanism of action Often unknown Usually
known
Toxicological tests Usually not avail-
able in animals
Mandatory
Empirical data Very important Often mean-
ingless
Speciﬁc adverse
eﬀects
Rare through
experience
Frequent
Tolerance of therapy Usually good Limited
Therapeutic window Wide Usually nar-
row
Suitability for chronic
use
Often well tested Not yet tested
for new drugs
Placebo controls Diﬃcult to achiev-
able
Achievable
Controlled clinical
trial
Usually not avail-
able
Mandatory1.4. The concern over quality, safety and eﬃcacy of herbal
medicine
CM herbs and their manufactured products have
been used for thousands of years for prevention and
treatment of diseases in China apart from recently in-
troduced synthetic pharmaceuticals in orthodox medical
(OM) practice since the late 1800s. When used or pre-
scribed according to Chinese medical philosophy and
practice, through test of time, those medications and
crude materials recorded in the Chinese Pharmacopoeia
have been approved for safe use (The Pharmacopoeia
Commission of PRC, 2000). The previously mentioned
unfavourable incidents have possibly been due to un-
professional practice and shortage of supply. Neverthe-
less, all medicinal products used in humans and animals
should have proven QSE. Problems and diﬃculties arise
in the quality assurance of herbal medicinal products
because there are so many unidentiﬁed chemical entities
in the ﬁnished products, and the actual bioactive com-
ponents are seldom known. Recent advances in analy-
tical chemistry and related disciplines have helped
elucidating the complex chemical compositions of CM
herbs. Table 3 summarises the diﬀerences between or-
thodox drugs and CM materials (both crude herbs,
known as Ying Pin, and ready-made or proprietary
products).
Chemical analytical techniques can be applied at
diﬀerent stages of good practices in quality assurance of
natural or herbal products, including Good Agricultural
Practice (GAP), Good Sourcing Practice (GSP), Good
Laboratory Practice (GLP), Good Manufacturing
Practice (GMP), and Good Clinical Trial Practice(GCTP). This review paper addresses how using modern
analytical methodologies to assess contaminants that
may be detected from these materials. Data from these
analyses will provide a range limit accepted generally
according to guidelines for food substances. We can
Table 4
Some pharmacologically active principles isolated from Chinese
medicinal plants (adopted from Chan (1995))
Chemical type Number of compounds isolated
Alkaloids 213
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of CM or other herbs and their ready-made products.
Diﬀerent government bodies from diﬀerent countries
will have diﬀerent regulatory controls over products
from herbal or natural sources (Chan, 1997).Terpenes
Monoterpenes 36
Sesquiterpenes 39
Diterpenes 49
Triterpenes 65
Cardiac glucosides 25
Phenolic compounds
Quinonis 34
Chromones 9
Flavonoids 49
Coumarins 34
Lignans 42
Phenyl propanoids 25
Others 75
Acids, amides and
miscellaneous
66
Total 7612. Advances in chemical analytical and biomedicial
screening technology
2.1. Chemical analytical systems
For the past 40 years, chromatography and spec-
troscopy have been used to study chemical compositions
of CM herbs and plants. Using the methods of gas
chromatography (GC), high performance liquid chro-
matography (HPLC), ultra-violet spectroscopy (UV),
infra-red spectroscopy (IR), Raman spectroscopy, nu-
clear magnetic resonance spectroscopy (NMR), mass
spectroscopy (MS), X-ray diﬀraction, GC–MS and
HPLC–MS, many chemical compounds from CM herbs
have been isolated and identiﬁed. Recently, capillary
electrophoresis has been used to infer the botanical
sources and to assess the quality of Ephedrae Herba (Liu
et al., 1993), Coptidis Rhizoma (Liu et al., 1994), Ginseng
Radix (Chuang et al., 1995) and Paeoniae Radix (Chu-
ang et al., 1996). Increased sensitivity has been achieved
by coupling HPLC or GC with other analytical systems.
For instances, the combination of liquid chromato-
graphy and tandem mass spectrometry was eﬃcient to
detect co-eluting, closely related substances (Covey et al.,
1986) and to quantify active components from tradi-
tional Chinese medicine over a concentration range of
1 ng/ml to 10 lg/ml (Wang et al., 1997).
The successes of eventual launching new drugs using
these conventional approaches have been very disap-
pointing (Chan, 1995) even though several eﬀective
single chemical entities have been found, some with their
deﬁnite chemical structure modiﬁcations (Table 4). In
CM practice, synergistic actions provided by some
chemically unknown or not isolated ingredients in
composite prescriptions have proven eﬀectiveness from
double blind clinical trials. Thus these analytical meth-
ods may not be appropriate for quality/eﬃcacy assur-
ance.
2.2. Biomedical screening systems
Problems related to chemical analysis have been
identiﬁed that the level of the active (secondary meta-
bolites) components may be aﬀected by physiological
conditions, harvesting period and storage conditions.
Moreover, closely related plant species may contain
similar chemical components from which a deﬁnite bo-
tanical identiﬁcation is not always possible. In some
cases, the chemicalmethodusually requires large amountsof samples for a proper analysis and some of the in-
struments such as HPLC; capillary electrophoresis and
mass spectrometry are expensive and may not be avail-
able in many analytical laboratories.
Classical cytogenetic methods including chromosome
counting and karyotyping may also be used to diﬀer-
entiate medicinal materials (Honda et al., 1994) and play
a role in assessing hybridity of plants (Magdalita et al.,
1997). Nevertheless, it is not useful in diﬀerentiation of
closely related species. Proteins have been exploited as
identiﬁcation markers in Epimedium species (Koga et al.,
1991), and to diﬀerentiate inter- and intra-species of
Panax ginseng (Sun et al., 1993; Koren and Zhuravlev,
1998). One of the drawbacks of such markers is that the
protein patterns vary in diﬀerent tissues, developmental
stages and environment as a consequence of temporal
and spatial gene expression. Distinguishable markers
may also not be easily detected in closely related species
and protein is prone to degradation after prolonged
storage of the herbs.
DNA molecules are reliable markers for informative
polymorphisms as the genetic composition is unique for
each individual and is less aﬀected by age, physiological
conditions as well as environmental factors. Additional
advantages of DNA markers include: Firstly, small
amount of sample is suﬃcient for the analysis, which is
particularly relevant for CM materials that are expen-
sive or in limited supply, and secondly, the physical form
of the sample for assessment does not restrict detection.
The DNA materials can be extracted from leaves, stems
or roots of the herbal materials. Therefore DNA ﬁn-
gerprinting can be very useful to assess and conﬁrm the
species of the plant materials of interest.
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in situ or ex vivo techniques for pharmacological and
toxicological screening may be more appropriate for
screening purposes for the bioactivities of CM herbs and
products as most of the CM formulary products are in
combinations of multiple herbs. These techniques can be
applied for the studies of other herbal medicinal mate-
rials using their crude extracts or bio-active fraction-
guided approaches.3. Sources of toxic chemicals and contaminations in herbal
products
The practices of most ethnic herbal medicine include
the use crude or raw herbs that are collected from the
wild or from cultivated ﬁelds and their prepared or
ready-made (formulated mixture of herbal or other
natural materials) products. Toxic contaminants may
come from:
• Environments and conditions that the medicinal
plants are grown or collected.
• The conditions under which they are dried and pro-
cessed.
• The storage conditions and conditions during trans-
port.
• The manufacturing processes when the ready-made
medicinal products are produced.
3.1. The use of potent and toxic medicinal materials in
Chinese medicinal prescriptions
Some CM natural herbs listed in the oﬃcial Chinese
Pharmacopoeia, CP (The Pharmacopoeia Commission
of PRC, 2000) are considered poisonous or toxic due to
the presence of poisonous or toxic chemical constituents
in the herbs. Of which about 50 of animal, plant and
mineral natural materials are included in the CP. In CM
they are seldom prescribed or used alone. In the CP the
words ‘‘toxic, non-toxic, very toxic or slightly toxic’’ are
often used in describing Chinese Materia Medica. Non-
toxic herbs, sometimes referred to as Superior Class,
are moderate or mild in nature and, generally speaking,
do not possess any side eﬀects. Toxic herbs, sometimes
referred as Low Grade herbs and used for speciﬁc
purposes in a traditional CM prescription, can cause
symptomatic reactions and adverse eﬀects. No overdose
of these should be prescribed or given. Examples are
processed aconite root (Fuzi) and Nuxvomica seed
(Maqianzi) as cited in the present Compendium.
CM herbs are often prescribed in Fu-Fang (composite
formulae) according to CM principles of diagnosis and
treatment. This approach of combining of processed
poisonous or toxic herbs and non-toxic herbs with the
latter neutralises or reduces the toxicity of the poisonousherbs. The diﬀerent characteristics of herbs in a given
prescriptions, consumed orally as aqueous decoction,
rectiﬁes the hyper-activity or hypo-activity of Yin and
Yang in the unwell body, consequently curing the dis-
eases that have caused the imbalance of Yin and Yang,
and restoring health. Diﬀerent combinations of herbs
can cause variation in therapeutic eﬀects. Traditionally
the result of combining herbs can be classiﬁed as mutual
reinforcement; mutual assistance; mutual restraint or
mutual counteraction; mutual suppression; and mutual
antagonism. Based on the CM principles of Fu-Fang-Xue
(Studies of Herbal Combination), the poisonous herbs
present in formulae have been included in some well-
used prescriptions over a long period of time according
to recorded experience. The poisonous herbs that are
included in Fu-Fang should be processed according to
laid down procedures listed in the Pharmacopoeia or
other CM guidebooks.
3.2. General considerations on how CHM products
produce toxic eﬀects when not used properly
Similar to using orthodox medicines it is understood
that all drugs are toxic at high doses. Although the 48
CM materials described in the Pictorial Compendium
for potent and poisonous CMMs (Xu and Chan, 1994)
are recorded in Pharmacopoeia as poisonous herbs they
are used, after special treatments according to tradi-
tional processing procedures, in herbal combinations
with other non-toxic herbs according to CM diagno-
sis and treatment. With practice experience and good
knowledge of CM herbs the practitioners seldom come
across any problems (Chan, 2002). Among many fac-
tors, possible reasons for occurrence of adverse eﬀects
and toxicity in using CM are discussed.
3.2.1. Authenticity or poor quality of CM herbs
Popularity and scarcity of certain CM herbs may
encourage traders to sell poor quality herbs. Misuse and
confusion of names of certain CM herbs enhances dif-
ﬁculty in identifying the correct herbs in the market.
Some traders supply fake herbs that are poisonous.
Substitution or adulteration with more toxic herbs
may occur erroneously, when the herb is incorrectly
identiﬁed, or deliberately for economic reasons when a
cheaper herb is supplied to replace a safer, more ex-
pensive one. The most widely publicised reports were the
cluster of cases of rapidly progressive interstitial neph-
ritis in Belgium (Vanhaelen et al., 1994). Following
investigation, this problem was attributed to the sub-
stitution of Aristolochia fangchi instead of the CM herb
Stephania tetrandra in a combined slimming regimen
that included some orthodox medications. Aristolochic
acid from Aristolochia fangchi is a known nephrotoxin,
and the other orthodox drugs present such as aceta-
zolamide in the slimming medication could have poten-
K. Chan / Chemosphere 52 (2003) 1361–1371 1367tiated this toxic eﬀect. Most of the cases involved were
young women, and some developed irreversible end-
stage renal failure and/or carcinoma in the urinary tract.
3.2.2. The consequence of processing of CM crude herbs
All CM herbs are processed or prepared from fresh
after collection with appropriate procedures before use.
The processing, apart from cleaning and preserving
purposes, removes or reduces the toxic components in
the unprocessed crude herbs which when taken alone
will cause fatal eﬀects. Certain processing changes the
eﬀects of some herbs. For example, raw Radix Reh-
manniae is mainly used to purge heat, or cool the blood
and promote the generation of body ﬂuids. But Radix
Rehmanniae Preparata has a warm property and is es-
pecially eﬀective for enriching blood. After processing
the therapeutic eﬀects of some herbs will be enhanced.
For example, Rhizoma Corydalis processed with vinegar
has greater analgesic eﬀect. If the supplied herbs in the
market of developed countries have not been processed
properly could lead to toxicity, especially so when used
without composite prescriptions (Chan, 2002).
3.2.3. The quantity of CM herbs prescribed
This refers to the dosage of each herb used in the
composite prescriptions––(Fu-Fang) and depends on
how well trained and experienced is the practitioner who
prescribes. General guidelines are listed in each of the
monographs of CM herbs and composite formulae as
reference for use. Thus overdosing should be avoided.
This is also related to the quality of herbs supplied.
Potent or poisonous herbs, if not properly processed and
checked, will produce adverse eﬀects even when used as
components in composite formulae.
3.2.4. The likelihood for interaction of drug–CM products
interactions
Reports have reviewed potential interactions between
herbal medicines and drugs. These have focused mainly
on the herbs used in the west especially for ginseng and
ginkgo biloba, which are widely used in Asian countries.
Ginseng has been reported to interact with phenelzine
and other monoamine inhibitors causing a central ner-
vous system (CNS) stimulant eﬀect (Jones and Runikis,
1987). The anticoagulant eﬀect of warfarin was de-
creased when ginseng was also taken simultaneously
(Janetzky and Morreale, 1997). Digoxin levels were ele-
vated in a patient who took a preparation labeled as
Siberian ginseng, Eleutherococcus senticosus, (McRae,
1999), but there were no signs of toxic eﬀects. We re-
ported the clinical observations on interactions between
some popular CM herbs and warfarin with experimental
animal studies. Danshen (Salvia miltiorrhiza) had eﬀects
on both the pharmacodynamics and pharmacokineties
of warfarin in rats (Lo et al., 1992), whereas danggui
(Angelica sinensis) aﬀected the pharmacodynamics butnot the pharmacokinetics of warfarin in rabbits (Lo
et al., 1995).
However, there are very few publications in the En-
glish language that report interactions between CM
substances and orthodox drugs. We have recently com-
piled a list of CM and drug interactions (Chan and
Cheung, 2000). We have also observed that not all in-
teractions between CM products and orthodox drugs
are harmful; some were beneﬁcial when both CM
products and OM drugs are combined. All commonly
used CHM crude herbs and ready-made CM products
have been listed against orthodox drugs for warning of
likely and clinically important herb-drug interactions.
3.3. The conditions of the patients’ welling being and
disease state
Many patients are very ill by the time they consult the
CM practitioners. Some would consider CM treatment
as their last hope for recovery. The incidents of adverse
eﬀects could be higher in this group of patients. Because
of the aging processes many elderly patients would have
compromised body functions; in particular, the cardio-
vascular system, liver function, and renal function.
Moreover many of these patients have been undergone
poly-pharmacy scheme of drug treatments. Therefore
the likelihood for occurrence of drug-CHM products
interactions is relatively high in this subgroup.4. Literature reports on the presence of heavy metals,
pesticides, and orthodox drugs in herbal products
Contamination or adulteration of CM products with
heavy metals such as lead, mercury, cadmium, arsenic,
or thallium is of concern. A number of case reports have
been published (Wu, 1992; Wong et al., 1993; Ueng et al.,
1997; Liang et al., 1998; Au et al., 2000; Koh and Woo,
2000), and the problem was discussed in the following
sections. However some CM products do contain heavy
metals as essential ingredients. The poor quality control
of these products causes health hazard as some products
may present unusually high concentrations of potent
and poisonous ingredients that could lead to fatality if
consumed. The presence of pesticides, excessive micro-
bial growth and orthodox drugs in some herbal products
has been reported:
• A review article (Koh and Woo, 2000) with 58 refer-
ences reported excessive toxic heavy metals and un-
declared drugs in Chinese proprietary medicines
(CPM) in Singapore between 1990 and 1997. The
names, uses, toxic heavy metals or drugs detected
and the year of detection are tabulated. Information
on the brand or manufacturers name are pro-
vided whenever available. The public and health care
1368 K. Chan / Chemosphere 52 (2003) 1361–1371professionals should be better informed of the basic
concept of traditional CM and its usefulness, as well
as the potential adverse eﬀects associated with its use.
Greater control over the safety and quality of CPM
could be achieved through GMP, regulatory control,
research, education, reporting usage of Chinese med-
icine (as in drug history) as well as reporting of ad-
verse events.
• Lead, arsenic, mercury and any undeclared drugs
have been detected in CPM using ICP/MS and atom-
ic absorption spectroscopy. A database for the CPM
was established and used to educate the public, the
herbal industry and medical professionals (Au et al.,
2000).
• In a research report (Liang et al., 1998), the authors
measured various metallic elements by atomic ab-
sorption spectrophotometer (K, Na, Mg, Ca, Fe,
Cu, Zn, Mn, Co, Cr, Ni, Mo and heavy metals As,
Pb, and Cd) in some Chinese herbal medicines. The
results showed: Lonicera japonica Thunberg dry ﬂow-
ers (each 100 g) had potassium ion 1.11 g, magnesium
ion 9.43 mg, copper ion 2.76 mg, zinc ion 5.06 mg,
Radix Glycyrrhiza uralensis Fischer et DCs (each
100 g) had magnesium ion 37.2 mg, calcium ion
358.8 mg, heavy metals detected in Lonicera japonica
Thunberg’s dry ﬂos and Radix Morinda oﬃcinalis
How’s (each 100 g), the arsenic ion was over 10 mg.
• A review (Ueng et al., 1997) with 51 references sum-
marized the toxicity of some commonly used tradi-
tional CMs in terms of acute, systematic, genetic,
analytic, and clinical toxicology. Acute toxicity study
showed that herbal medicines and their chemical con-
stituents exhibited LD50 values ranging from the
practically non-toxic to super-toxic categories. Target
organs of traditional CM-induced toxicity investi-
gated including liver, kidney, gastrointestinal tract,
nervous, and cardiovascular systems. Some TCM
showed mutagenicity by the Ames test, increased
the incidence of unscheduled DNA synthesis, micro-
nucleus formation, and chromosomal aberration in
cytogenetic assays. Some TCM products were con-
taminated with pesticides and heavy metals and adul-
terated with western drugs. Improper dispensing and
use of traditional CMs and individual idiosyncracy
may result in adverse eﬀects and fatalities. The paper
suggested that future TCM research, new drug devel-
opment, and safety evaluation should require ade-
quate toxicity testing and mechanistic toxicological
studies.
• A research article (Wong et al., 1993) reported the
concentrations of nine heavy metals, cadmium, co-
balt, copper, iron, manganese, nickel, lead, zinc,
and mercury in 42 Chinese herbal medicinal (CHM)
plants spectrophotometrically. Generally, the sam-
ples contained, relative to the other trace metals,
higher concentrations of iron, manganese, and zinc.The concentration range of the metals was compara-
ble to that reported in many of the East Asian vege-
tables and fruits. A few samples contained relatively
higher concentrations of toxic metals such as cad-
mium, lead, and mercury. This report suggested that
the presence of heavy metals was probably caused by
contamination during air-drying and preservation.
• A review (Wu, 1992), with 45 references, reported
studies of metabolism and toxicity of trace elements
and revealed important interactions between heavy
metals (Cd, Pb, and Hg) and some essential trace el-
ements such as Zn, Fe, Se, Cu, Cr, and Mn. In gen-
eral, a deﬁciency of these essential trace elements
increased the toxicity of heavy metals, whereas excess
appeared to be protective. These suggest that the
presence of the dietary essential trace elements may
contribute to the protection of man from the detri-
mental eﬀect of heavy metal exposure, while their de-
ﬁciency may increase toxicity. Some traditional
Chinese drugs are especially rich in essential trace ele-
ments. Appropriate use of these CM materials in
dietary manipulation might be valuable in the preven-
tion and treatment of heavy metal poisoning and
maintenance of healthy conditions.5. Conclusion: the way forward for assurance of quality,
safety and eﬃcacy of herbal medicines
5.1. Basic research on herbal medicines
Although herbal medicines have been used in clinical
practice for thousands of years, basic research pro-
grammes on CM substances should be focused on the
toxicity and eﬃcacy relationship for those potent and
poisonous herbal substances according to the principles
as practiced in Chinese medicine with doses applied for
composite formulae.
To overcome those environment factors that are re-
lated to contaminations from pesticide residues and
heavy metals there should be control measures to im-
plement necessary standard operating procedures (SOP)
for GAP and Good Sourcing Practice (GSP) at source.
GLP and GMP are also needed to produce good quality
medicinal products from herbal or natural sources.
Due to the particular concern of toxicity, poor
quality and adulteration of ready-made herbal medicinal
products in the market the priority of research on
product-related treatment, in particular herbal products,
is to ensure QSE of the end products used by consumers.
For the majority of cases, the biologically active chem-
ical compounds of these products are unknown even
other known chemical entities have been isolated. It has
also been shown that single compound isolated from
organic solvents is either too toxic or with no thera-
peutic activities. Most traditional medicinal herbs are
K. Chan / Chemosphere 52 (2003) 1361–1371 1369used in the form of an aqueous decoction. Therefore
research projects should be centred on development of
analytical and biological procedures for use to give the
quality assurance and control, and clinical assessment of
eﬃcacy and safety of these products. I have been in-
volved with institutes in China to develop procedures
linking analytical with bio-activity patterns or ﬁnger-
printings follow by fuzzy logic computing techniques for
interpretation on CM herbs and herbal prescriptions
(oﬃcial Fu-Fang mixtures of several herbs, administered
as decoction). After a series of training set inputs of
using authenticated aqueous herbal extracts, individual
herbs or mixtures of herbs, a standard pattern is used as
the reference guide for subsequent assessment. This type
of approaches will generate patterns as reference and for
prediction and recognition purposes for further research
on individual pure active chemical entities (Chan et al.,
1995).
5.2. Regulatory aspects
All CM or other ethnic herbal products when sup-
plied, as medications, should be regulated for safety,
quality and for appropriate evidence of eﬃcacy. It ad-
vocates the establishment of a new category of licensed
herbal medicines, prepared in accordance with current
Good Manufacturing Procedures (cGMP), which meet
standards of safety and quality, and which are regulated
by local government health department that should have
reciprocating arrangements with organizations such as
the Medicines Control Agency in the UK, FDA in the
USA and those in the European Union.
The licensing requirements in this new category (i.e.
herbal medicines) may not be as demanding as those
currently apply to licensed medicines. Speciﬁcally, the
‘‘level of proof’’ of activity may not need to be as high as
for allopathic medicines. Eﬃcacy may be accepted on
the basis of documentation of traditional use over a long
period, as suggested by WHO.
Safety may deem to have been demonstrated by vir-
tue of traditional use. However, these products ought to
be required to substantiate a history of safe use, pref-
erably in the EU for the dosage and indications for
treatment to be approved, and the license should clearly
indicate the inappropriate conditions of use (contra-
indications). It would be dangerous to agree product
safety as the basic, default position. In addition, the
‘‘test of time’’ criterion detects common acute adverse
events, but not rare adverse events or those with a long
latency. Also, todays users of herbal remedies may diﬀer
from those in earlier eras.
The governmental departments in China, such as
State Administration of Traditional Chinese Medicine
and State Food and Drug Administration, issue regu-
lations and registration guidelines and procedures for
CHM products. Consultation with these guidelines willhelp to set up regulations in the UK or other developed
countries for CHM products. Consultation of the
Commission E structure from Germany will also help to
formulate Regulatory Guidelines for herbal products as
medicines.
There is a need for regulation on the quality assur-
ance of both practitioners and products-related treat-
ment involving herbal products for medicinal uses. In
the case of CHM products in the UK nearly all of them
are imported. Some are manufactured from imported
dried granules by small herbal ﬁrms. They are crude
herbs and ready-made products of well-used prescrip-
tion products. Quality assurance and control of these
have been loose and unsatisfactory. They reach the UK
market probably as food or under the nutritional cate-
gory. There is a lack of expertise in checking the identity
of herbs. Language problem is another aspect as herbal
ingredients are supplied with similarly named substitutes
that could be toxic. Appropriate regulations may help to
sort out problems on the quality assurance and control
issues.
One way of giving guidelines for regulation is to spell
out monographic control of imported herbs and herbal
products. For some herbs used in the EU there are
monographs issued for all of them in common use. The
Commission E in Germany has produced standard
monographs for controlling herbal medicines. ESCOP
has commissioned the writing of standards for over 50
European herbs. With quality of herbal medicinal
products assured the eﬃcacy of them can be assessed by
randomised clinical trials (RCT) before licenses can be
issued. The drawback of such procedures will certainly
single out cow-boy practice, but also discourage man-
ufacturers to register their products as medicines due to
the high cost for getting the licences. An alternative
approach should be found without compromising the
issue on QSE of these products.References
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